Table Graph
      published meta-analysis   sensitivity analysis   studies

sarilumab high dose (400mg) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] 0.97[0.38; 2.50]Lescure (Sarilumab 400mg), 202110%257NAnot evaluable serious adverse eventsdetailed resultsLescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] 1.38[0.76; 2.51]Lescure (Sarilumab 400mg), 202110%259NAnot evaluable adverse eventsdetailed resultsLescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] 1.31[0.76; 2.27]Lescure (Sarilumab 400mg), 202110%259NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-19 01:21 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 646 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons